ADMA Biologics (NASDAQ:ADMA) PT Raised to $6.00

ADMA Biologics (NASDAQ:ADMAGet Rating) had its target price raised by equities researchers at Mizuho from $5.00 to $6.00 in a research note issued on Thursday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Mizuho’s price objective suggests a potential upside of 83.49% from the stock’s current price.

A number of other analysts have also commented on the company. StockNews.com initiated coverage on ADMA Biologics in a research report on Wednesday, October 12th. They issued a “sell” rating for the company. HC Wainwright lowered their price objective on ADMA Biologics from $6.00 to $4.00 and set a “buy” rating for the company in a research report on Monday, July 25th.

ADMA Biologics Stock Performance

Shares of NASDAQ:ADMA opened at $3.27 on Thursday. ADMA Biologics has a twelve month low of $1.17 and a twelve month high of $3.34. The firm has a market cap of $642.09 million, a PE ratio of -8.84 and a beta of 1.00. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.73 and a current ratio of 7.94. The business has a fifty day moving average of $2.65 and a 200-day moving average of $2.31.

ADMA Biologics (NASDAQ:ADMAGet Rating) last announced its earnings results on Wednesday, August 10th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. The company had revenue of $33.91 million during the quarter, compared to analyst estimates of $31.17 million. ADMA Biologics had a negative return on equity of 54.78% and a negative net margin of 66.44%. During the same period last year, the company posted ($0.15) earnings per share. On average, equities research analysts predict that ADMA Biologics will post -0.31 EPS for the current fiscal year.

Hedge Funds Weigh In On ADMA Biologics

Several institutional investors have recently modified their holdings of ADMA. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of ADMA Biologics during the 1st quarter worth about $40,000. Assenagon Asset Management S.A. grew its position in shares of ADMA Biologics by 283.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 503,400 shares of the biotechnology company’s stock worth $921,000 after buying an additional 371,956 shares during the period. Stratos Wealth Partners LTD. acquired a new position in shares of ADMA Biologics during the 1st quarter worth about $73,000. Sciencast Management LP acquired a new position in shares of ADMA Biologics during the 1st quarter worth about $123,000. Finally, Qube Research & Technologies Ltd grew its position in shares of ADMA Biologics by 41.6% during the 1st quarter. Qube Research & Technologies Ltd now owns 148,080 shares of the biotechnology company’s stock worth $271,000 after buying an additional 43,520 shares during the period. 60.77% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

(Get Rating)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Featured Stories

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.